Efficacy and Safety of Colchicine in Prevention of Secondary Cardiovascular Outcomes Among Patients With Coronary Vessel Disease: A Meta-Analysis

Lubna Sattar 1, Rahat A. Memon 2, Fatima Ashfaq 3, Syed Shah Qasim Hamdani 4, Rimsha Rahim Vohra 5, Jibran Ashraf 6, Baseer Khan 7, Noman Khurshid Ahmed 8, Areeba Khan 9

1. Medicine, Shadan Institute of Medical Sciences, Hyderabad, IND 2. Internal Medicine, Abington Memorial Hospital, Abington, USA 3. Internal Medicine, Nishtar Medical University, Multan, PAK 4. Medical College, Foundation University Medical College, Islamabad, PAK 5. Medical College, Dow University of Health Sciences, Karachi, PAK 6. Cardiology, National Institute of Cardiovascular Diseases, Karachi, PAK 7. Pathology, United Medical and Dental College, Karachi, PAK 8. Critical Care Medicine, United Medical and Dental College, Karachi, PAK

Corresponding author: Rahat A. Memon, rahatahmed227@yahoo.com

Abstract

Coronary vessel disease (CVD) is a class of diseases that impacts the blood vessels and heart and is one of the leading causes of disability and death. CVD includes cerebrovascular disease and coronary heart disease, both illnesses of the vessels transporting the oxygenated blood to the brain or heart. Colchicine is an inexpensive and old drug with strong anti-inflammatory effects. Numerous randomized control trials (RCTs) have demonstrated the effectiveness of low-dose colchicine for the prevention of severe cardiovascular events without showing any signs of serious adverse effects within the regime of treatment. In the current meta-analysis, we aim to assess the efficacy and safety of colchicine for secondary cardiovascular outcome prevention among patients with clinically proven CVD. The current meta-analysis was carried out using the preferred reporting items for systematic reviews and meta-analysis (PRISMA) guidelines. PUBMED, Cochrane, and EMBASE databases were used to search for RCTs comparing colchicine and placebos for the prevention of secondary cardiovascular outcomes. The primary efficacy endpoint was mortality due to cardiovascular disease, stroke, urgent coronary revascularization, and myocardial infarction. Secondary efficacy outcomes included death due to all-cause mortality. Seven RCTs were reviewed, with a pooled sample size of 12114, out of which 6099 were randomized to the colchicine group, and 6015 were randomized to the control group. The decrease in cardiovascular events, including myocardial infarction, stroke, urgent coronary revascularization, and cardiac-related death, was significantly lower in patients randomized to colchicine (p-value<0.05). The incidence of safety outcomes did not vary significantly different between groups (p>0.05). In patients with CVD, compared to standard medical therapy, colchicine significantly decreases the risk of cardiovascular events such as cardiovascular-related death, myocardial infarction, stroke, and urgent coronary revascularizations.

Introduction And Background

Coronary vessel disease (CVD) is one of the leading causes of disability and death [1]. CVD is a class of diseases that impacts the blood vessels and heart. It includes cerebrovascular disease and coronary heart disease, both illnesses of the vessels transporting the oxygenated blood to the brain or heart [2]. One of the vital pathophysiological mechanisms of CVD is the development of plaques, also known as atherosclerotic lesions [3]. These lesions can result in organ damage, such as heart failure, as well as chronic ischemia. But these plaques can potentially burst, leading to sudden thrombotic events like strokes or myocardial infarctions [4]. Inflammatory processes appear to have a significant part in the mechanisms that cause atherosclerotic plaques to become unstable and then rupture [4,6].

The suggested treatment for atherosclerosis and coronary artery disease (CAD) in clinical guidelines reflects the complexity of the condition [5]. The comprehensive approach to patient care combines lifestyle changes with medication interventions, such as lipid-lowering therapy, blood pressure management, glucose control, and antithrombotic therapy [4]. These treatments have been shown as effective at slowing the development of atherosclerosis or drastically lowering the frequency of cardiovascular outcomes [5]. Inflammation has become a significant therapeutic target in individuals with atherosclerosis in recent times [6]. This therapeutic impact was more noticeable in patients who successfully reduced their inflammatory indicators. As a result, cardiovascular events because of plaque destabilization and rupture were decreased [7-8].

Colchicine is an inexpensive and old drug with strong anti-inflammatory effects. It has been used for the treatment of different diseases such as gout, pericarditis, primary biliary cirrhosis, Behçet’s disease, and...
familial Mediterranean fever [9]. Besides this, colchicine is a comparatively safe and low-cost drug that has been available for several centuries [10]. Numerous randomized control trials (RCTs) have demonstrated the effectiveness of low-dose colchicine for the prevention of severe cardiovascular events without showing any signs of serious adverse effects within the regime of treatment [11-12]. Colchicine may hinder the inflammatory mechanism causing the destabilization or development of atherosclerotic plaques. Colchicine is also associated with the reduction of high-sensitivity C-reactive protein in individuals with CAD [13].

In recent times, the role of colchicine in the prevention of secondary cardiovascular events has been the focus of extensive research. In the current meta-analysis, we aim to assess the efficacy and safety of colchicine for secondary cardiovascular outcome prevention among patients with clinically proven CVD.

**Review**

**Methodology**

The current meta-analysis was carried out using the preferred reporting items for systematic reviews and meta-analysis (PRISMA) guidelines. PUBMED, Cochrane, and EMBASE databases were used to search for RCTs comparing colchicine and placebo for the prevention of secondary cardiovascular outcomes. Key terms used for searching for relevant articles included "colchicine" "coronary artery disease", "cardiovascular outcomes", "secondary prevention" and "cardiovascular disease".

Two reviewers independently screened titles and abstracts of all the potential studies for inclusion. Any disagreement between the two reviewers was resolved through discussion or with the consensus of the third reviewer. Full-text was retrieved from all relevant articles, and two reviewers independently screened the full-texts articles to assess for inclusion criteria.

Articles that fulfilled the following criteria were included in the current meta-analysis: 1) the study compared colchicine to placebo, no colchicine or standard management for prevention of secondary cardiovascular outcomes 2) the study reported at least one cardiovascular outcome, 3) the study followed up patients to at least one month. Studies that were published in a language other than English were excluded. Besides this, studies were excluded if they compared one dose of colchicine with another dose. No restrictions were placed on the time and place of publication.

From the eligible articles, data on study characteristics such as first author, year of publication, sample size, intervention, the mean age of participants, major inclusion criteria, and median follow-up period were extracted and presented in the form of a table.

**Assessment of risk of bias**

Two authors assessed the risk of bias independently for each included study utilizing the criteria defined in the Cochrane Handbook for Systematic Reviews of Interventions. Any disagreement between the two reviewers was resolved through discussion or with the consensus of another review author. Six domains were assessed to evaluate the risk of bias, including random sequence generation, allocation concealment, blinding of personnel and participants, blinding of outcomes assessment, incomplete outcome data, selective outcome reporting, and other biases.

**Outcome assessment**

The primary efficacy endpoint was mortality due to cardiovascular disease, stroke, urgent coronary revascularization, and myocardial infarction. Secondary efficacy outcomes included death due to all-cause mortality. Safety outcomes were assessed by comparing the adverse events and serious adverse events such as gastrointestinal events, infection, cancer, pneumonia, and other adverse events between the colchicine group and control group.

**Statistical analysis**

Analysis was performed using Cochrane Review Manager, version 5.4 (Cochrane, London, United Kingdom). For dichotomous data, pooled risk ratios (RR) were calculated along with a 95% confidence interval (CI) using the Mantel Haenszel method. Heterogeneity analysis was performed by calculating the I2 value. If the value of I2 is less than 50, data was considered homogenous and analyzed using a fixed-effect model. Otherwise, a random effect model was chosen. Forest plots were produced to show the relative effect size of colchicine versus the control group on efficacy and safety outcomes. A p-value of 0.05 or less was considered statistically significant.

**Results**

Through systematic search, 92 studies were identified, as shown in Figure 1. After removing duplicates, the title and abstract of 86 studies were screened. Only 25 studies were eligible for full-text screening. Of these, only seven studies were used in the current meta-analysis [10-12,14-17]. Characteristics of all included studies are shown in Table 1.
The pooled sample size of enrolled patients was 12,114, out of which 6099 were randomized to the colchicine group and 6015 were randomized to the control group. The control group was either placebo or no medicine or standard care. Four studies had a follow-up period of 12 months or more [10-12,14] while three studies had a follow-up time of less than 12 months [15-17]. Among all included studies, three studies were multi-centered [10,12,14].
| Author          | Publication Year | Inclusion Criteria                                                                 | Groups                                           | Sample Size | Mean Age | Multicenter (Yes/No) | Median Follow-up Time |
|-----------------|------------------|-------------------------------------------------------------------------------------|-------------------------------------------------|-------------|----------|----------------------|------------------------|
| Akodad et al.   | 2017             | Patients with ACS and treated with PCI                                             | Colchicine 1 mg for one month                    | 23          | 59.9 years | No                   | One month              |
|                 |                  |                                                                                     | Conventional treatment                           | 21          |          |                      |                        |
| Deftereos et al. | 2013             | Patients with CVD                                                                    | 0.5 mg twice daily for six months                | 140         | 66.7 years | No                   | Six months             |
|                 |                  |                                                                                     | Placebo                                          | 139         |          |                      |                        |
| Nidorf et al.   | 2013             | Patients with angiographically proven coronary disease                              | Colchicine 0.5 mg once daily                     | 282         | 67.5 years | No                   | 24 months              |
|                 |                  |                                                                                     | Placebo                                          | 250         |          |                      |                        |
| Nidorf et al.   | 2020             | Patients with coronary disease                                                       | Colchicine 0.5 mg once daily                     | 2762        | 65.8 years | Yes                  | 28.6 months            |
|                 |                  |                                                                                     | Placebo                                          | 2760        |          |                      |                        |
| O Keefe et al.  | 1992             | Patients with ACS undergoing PCI in a coronary artery                                | Colchicine 0.6 mg for six months                 | 130         | 60.5 years | No                   | Six months             |
|                 |                  |                                                                                     | Placebo                                          | 67          |          |                      |                        |
| Tardif et al.   | 2019             | Patients having myocardial infarction within 30 days of enrollment                  | Colchicine 0.5 mg once daily                     | 2366        | 60.5 years | Yes                  | 22.6 months            |
|                 |                  |                                                                                     | Placebo                                          | 2379        |          |                      |                        |
| Tong et al.     | 2020             | Adults presented with ACS and had evidence of CAD                                   | 0.5 mg oral colchicine twice daily for the first month, followed by 0.5 mg daily for 11 months | 396         | 59.8 years | Yes                  | 12 months              |
|                 |                  |                                                                                     | Placebo                                          | 399         |          |                      |                        |

**TABLE 1: Characteristics of included studies**

ACS: acute coronary syndrome; PCI: percutaneous coronary intervention; CAD: coronary artery disease

**Risk of bias in included studies**

The overall risk of bias was moderate. No indication of selection bias has been found in any of the studies, but allocation concealment was not clear in three out of seven studies. Blinded outcome assessment was frequently low, and only one study had a high blinded outcome assessment. Overall, the quality of the study was moderate. Figure 2 shows the risk of bias plot.

**FIGURE 2: Risk of bias graph**

**Effects of colchicine on secondary cardiovascular events**
Data on the incidence of cardiovascular-related deaths were available for four studies [10,12,14-15], including 11,341 patients (5662 in the colchicine group and 5679 in the control group). Overall, 43 deaths were reported in the colchicine group and 51 deaths were reported in the control group, and the difference is insignificant between the two groups (RR: 0.85; 95%CI: 0.57-1.27) as shown in Figure 3. There was insignificant heterogeneity between the results of included studies ($I^2 = 0\%$).

**FIGURE 3: Forest plot for cardiac-related death**

The pooled RRs with 95%CI were calculated using fixed-effects models. Weight refers to the contribution of each study to the overall pooled estimate of treatment effect. Each square and horizontal line denotes the point estimate and 95%CI for each trial’s RR. The diamonds signify the pooled RR; the diamond’s center denotes the point estimate and the width denotes the 95%CI.

RR: risk ratio

Data on urgent coronary revascularization were available in three studies [10,12,14]. A total of 11,062 patients were enrolled in these three RCTs (5524 in the colchicine group and 5538 in the control group). The risk of urgent coronary revascularization is 42% lower in the colchicine group as compared to the control group (RR: 0.58; 95%CI: 0.37-0.92), as shown in Figure 4. There was high between-study heterogeneity ($I^2 = 60\%$).

**FIGURE 4: Forest plot for urgent coronary revascularization**

The pooled RRs with 95%CI were calculated using random-effects models. Weight refers to the contribution of each study to the overall pooled estimate of treatment effect. Each square and horizontal line denotes the point estimate and 95%CI for each trial’s RR. The diamonds signify the pooled RR; the diamond’s center denotes the point estimate, and the width denotes the 95%CI.

RR: risk ratio

Data on stroke were available in four studies [10-13,14], including 11,594 patients (5806 in the colchicine group and 5788 in the control group). The risk of stroke was significantly lower in the colchicine group as compared to the control group (RR: 0.46; 95%CI: 0.28-0.74), as shown in Figure 5. There was insignificant heterogeneity between the results of included studies ($I^2 = 0\%$).
The pooled RRs with 95%CI were calculated using fixed-effects models. Weight refers to the contribution of each study to the overall pooled estimate of treatment effect. Each square and horizontal line denotes the point estimate and 95%CI for each trial's RR. The diamonds signify the pooled RR; the diamond's center denotes the point estimate, and the width denotes the 95%CI.

RR: risk ratio

Data on the incidence of myocardial infarction were available for five studies [10-12,14,17], including 11,640 patients (5829 in the colchicine group and 5811 in the control group). The risk of myocardial infarction is 25% lower in the colchicine group as compared to the control group (RR: 0.75; 95%CI: 0.62-0.90), as shown in Figure 6. There was insignificant heterogeneity between the results of included studies (I² = 43%).

FIGURE 6: Forest plot for myocardial infarction

The pooled RRs with 95%CI were calculated using fixed-effects models. Weight refers to the contribution of each study to the overall pooled estimate of treatment effect. Each square and horizontal line denotes the point estimate and 95%CI for each trial's RR. The diamonds signify the pooled RR; the diamond's center denotes the point estimate, and the width denotes the 95%CI.

RR: risk ratio

Data on all-cause mortality were available for five studies [10,12,14-16], including 11,538 patients (5794 in the colchicine group and 5744 in the control group). The relative risk of all-cause mortality was 1.14 (95%CI: 0.76-1.69), as shown in Figure 7. Heterogeneity between studies was low (I² = 28%).

FIGURE 7: Forest plot for all-cause mortality

The pooled RRs with 95%CI were calculated using fixed-effects models. Weight refers to the contribution of each study to the overall pooled estimate of treatment effect. Each square and horizontal line denotes the point estimate and 95%CI for each trial's RR. The diamonds signify the pooled RR; the diamond's center denotes the point estimate, and the width denotes the 95%CI.

RR: risk ratio

In sensitivity analysis of studies that included acute coronary syndrome (ACS) patients, the urgent coronary revascularization was significantly lower in the colchicine group as compared to the control group (RR: 0.45; 95%CI: 0.29-0.71), and heterogeneity reduced from 60% to 2%. Similarly, myocardial infarction was significantly lower in the colchicine group as compared to the control group (RR: 0.68; 95%CI: 0.53-0.88),
and heterogeneity reduced from 43% to 0%. Table 2 shows the sensitivity analysis, and the results are similar to the overall analysis.

| Outcome                        | Studies | RR (95% CI)     | Heterogeneity |
|--------------------------------|---------|-----------------|---------------|
| Cardiac-related death          | [10,14] | 0.93 (0.53-1.63)| 0%            |
| Urgent coronary revascularization | [10,14] | 0.45 (0.29-0.71)* | 2%              |
| Stroke                         | [10,14] | 0.29 (0.13-0.68)* | 0%            |
| Myocardial infarction          | [10,14,17] | 0.68 (0.53-0.88)* | 0%            |

**TABLE 2: Results of sensitivity analysis**

RR: risk ratio

*Significant at p-value<0.05

Safety analysis

The adverse events related to study medication or placebo reported by individual studies are shown in Table 3. No significant differences were reported in any of the adverse events between the colchicine and control groups as the p-value is more than 0.05. In both groups, the most common adverse events were gastrointestinal, being 15.68% and 14.30% in the colchicine group and control group, respectively.

| Adverse Event      | Colchicine n (%) | Control n (%) | RR (95% CI)     |
|--------------------|------------------|---------------|-----------------|
| Gastrointestinal events | 881 (15.68)   | 797 (14.30)   | 1.15 (0.94-1.41) |
| Cancer             | 163 (3.20)      | 168 (3.29)    | 0.97 (0.79-1.20) |
| Infection          | 188 (3.69)      | 182 (3.56)    | 0.77 (0.46-1.29) |
| Pneumonia          | 67 (1.31)       | 64 (1.25)     | 1.32 (0.48-6.63) |
| Others             | 64 (1.13)       | 143 (2.56)    | 0.47 (0.20-1.10) |

**TABLE 3: Adverse events**

RR: risk ratio

Discussion

The current meta-analysis was conducted to determine the efficacy and safety of colchicine for secondary cardiovascular outcome prevention among patients with clinically proven CVD. The current meta-analysis included seven RCTs, including 12,114 patients, out of which 6099 were randomized to the colchicine group, and 6015 were randomized to the control group with a median follow-up up to 28.6 months. The current meta-analysis found that the incidence of major cardiovascular events such as myocardial infarction, stroke, cardiac-related death, and urgent coronary revascularization was lower in the colchicine group as compared to the control group. In addition, colchicine has a favorable safety profile. Pooling RR from RCTs showed that the risk of major cardiovascular events was attributed to a risk decrease of 58%, 54%, and 25% for urgent coronary revascularization, ischemic strokes, and myocardial infarction, respectively. Pooled results showed that no significant difference is there in the incidence of all-cause mortality with colchicine between patients who received colchicine and patients in the control group.

Colchicine appears to have positive benefits in the prevention of cardiac disease, and plausible explanations for these effects have been put up. Colchicine has a broad anti-inflammatory impact [14]. It does not only target the NLRP3 inflammasome, whose activation causes the upregulation of IL-1 and IL-6 downstream but also disrupts microtubules and has antimitotic effects [18]. As cholesterol crystals within atherosclerotic plaques are known to cause local inflammation and provoke plaque instability, it is believed that colchicine may also be beneficial in treating cardiovascular illness through the suppression of these crystals [19].
Several observational studies have been conducted on the utilization of colchicine for the prevention of cardiovascular outcomes. These studies are limited to the prevention of CAD in patients with gout, liver disease, and without CAD at baseline [20-22]. The lower risk of cardiovascular outcomes in low-risk population further supports the role of colchicine in preventing the advancement of atherosclerosis and plaque destabilization, even though final conclusions cannot be derived from such observational research [22].

The utilization of colchicine for the prevention of primary or secondary cardiovascular outcomes will need longer terms to use. Based on experience treating famillial Mediterranean fever, it appears that there are few cases of late negative effects from very long-term continuous colchicine doses of up to 2 to 3 mg per day [23-24]. Long-term researches in individuals with cardiovascular illness at baseline are important in proving the safety of long-term lower dose therapy in this population. Among all the studies used in the current meta-analysis, four studies had a follow-up period of 12 months or more, while three studies had a follow-up time of fewer than 12 months.

Colchicine is prescribed widely, and it has a known side-effect and safety profile. It is considered a low-cost drug. In a meta-analysis conducted by Verma et al., including seven RCTs involving colchicine, the relative risk of discontinuation was because side effects was 4.34 (95% CI, 1.7-11.07) as compared to the placebo [25]. In the current meta-analysis, the most common adverse effects were gastrointestinal, but no significant differences were there between the gastrointestinal events in patients who received colchicine and those who got placebos. The meta-analysis conducted by Siak et al. included nine RCTs and also reported that the most common adverse effect is gastrointestinal symptoms such as vomiting, nausea, and diarrhea in up to 20% of the patients [26].

The current meta-analysis has certain limitations. Firstly, heterogeneity was there between the study populations enrolled in each of the trials that may describe the risk differences in cardiovascular outcomes between studies. In the current analysis, we tried to minimize the heterogeneity by performing a sensitivity analysis, in which studies involving ACS patients only were included. Furthermore, there were a limited number of studies; therefore, a statistical test for homogeneity may not have been optimal.

Conclusions
In patients with CVD, colchicine to standard medical therapy significantly decreases the risk of cardiovascular events such as myocardial infarction, stroke, and urgent coronary revascularizations. Even though the clinical benefit of colchicine in the prevention of secondary cardiovascular events has been shown in the current meta-analysis, exciting new data show its potential advantage for the prevention of secondary vascular outcomes in patients with clinically proven CVD. This advantage raises questions about the role of inflammation in both coronary disease and other inflammatory and immunomodulatory pharmacotherapies, which opens up new research directions.

Additional Information
Disclosures
Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

References
1. Global Status Report on Noncommunicable Diseases 2010. Alwan A (ed): World Health Organization, Geneva, Switzerland; 2010. https://apps.who.int/iris/bitstream/handle/10665/44579/9789240686458_eng.pdf.
2. Libby P: Mechanisms of acute coronary syndromes and their implications for therapy. N Engl J Med. 2015, 368:2004-13. 10.1056/NEJMr1216063
3. Shah PK: Inflammation and plaque vulnerability. Cardiovasc Drugs Ther. 2009, 23:51-40. 10.1007/s10557-008-4147-2
4. Shah PK: Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol. 2005, 41:155-225. 10.1016/s0735-1097(02)02834-6
5. Levine GN, Bates ER, Bittl JA, et al.: 2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol. 2016, 68:1082-115. 10.1016/j.jacc.2016.05.515
6. Ridker PM, Everett BM, Thuren T, et al.: Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017, 377:1119-31. 10.1056/NEJMoa1707914
7. Ridker PM, Libby P, MacFadyen JG, et al.: Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur Heart J. 2018, 39:5499-507. 10.1093/eurheartj/ehy310
8. Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ: Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet. 2018, 391:519-28. 10.1016/S0140-6736(17)32814-3
9. Terkeltaub RA, Furut DE, Bennett K, Kook KA, Crockett RS, Davis MW: High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. Arthritis Rheum. 2010, 62:1060-8. 10.1002/art.27327
10. Tardif JC, Kour S, Waters DD, et al.: Efficacy and safety of low-dose colchicine after myocardial infarction. N Engl J Med. 2019, 381:2497-505. 10.1056/NEJMoa1912388
11. Nidorf SM, Eikelboom JW, Budgen CA, Thompson PL: Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol. 2013, 61:404-10. 10.1016/j.jacc.2012.10.027
12. Nidorf SM, Fiolet AT, Mosterd A, et al.: Colchicine in patients with chronic coronary disease. N Engl J Med. 2020, 383:1838-47. 10.1056/NEJMoa2021372
13. Nidorf M, Thompson PL: Effect of colchicine (0.5 mg twice daily) on high-sensitivity C-reactive protein independent of aspirin and atorvastatin in patients with stable coronary artery disease. Am J Cardiol. 2007, 99:805-7. 10.1016/j.amjcard.2006.10.059
14. Tong DC, Quinn S, Nasis A, et al.: Colchicine in patients with acute coronary syndrome: the Australian COPS randomized clinical trial. Circulation. 2020, 142:1890-900. 10.1161/CIRCULATIONAHA.120.050771
15. Deftereos S, Giannopoulos G, Panagopoulou V, et al.: Anti-inflammatory treatment with colchicine in stable chronic heart failure: a prospective, randomized study. JACC Heart Fail. 2014, 2:131-7. 10.1016/j.jchf.2013.11.006
16. O'Keefe Jr JH, McCallister BD, Bateman TM, Kuhnlnein DL, Ligon RW, Hartler GO: Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty. J Am Coll Cardiol. 1992, 19:1597-600. 10.1016/0735-1097(92)90624-V
17. Akodad M, Lattuca B, Nagot N, et al.: COLIN trial: Value of colchicine in the treatment of patients with acute myocardial infarction and inflammatory response. Arch Cardiovasc Dis. 2017, 110:395-402. 10.1016/j.acvd.2016.10.004
18. Nidorf SM, Eikelboom JW, Thompson PL: Targeting cholesterol crystal-induced inflammation for the secondary prevention of cardiovascular disease. J Cardiovasc Pharmacol Ther. 2014, 19:45-52. 10.1177/10742484145499972
19. Kolackowski B, Thornton JW: Performance of maximum parsimony and likelihood phylogenetics when evolution is heterogeneous. Nature. 2004, 431:980-4. 10.1038/nature02917
20. Antoniou KM, Nicholson AG, Dimadi M, et al.: Long-term clinical effects of interferon gamma-1b and colchicine in idiopathic pulmonary fibrosis. Eur Respir J. 2006, 28:496-504. 10.1183/09031936.06.0002605
21. Almasio PL, Floreani A, Chiarainmonte M, et al.: Multicentre randomized placebo-controlled trial of ursodeoxycholic acid with or without colchicine in symptomatic primary biliary cirrhosis. Aliment Pharmacol Ther. 2000, 14:1645-52. 10.1046/j.1356-2036.2000.00869.x
22. Shah B, Toprover M, Crittenden DB, et al.: Colchicine use and incident coronary artery disease in male patients with gout. Can J Cardiol. 2020, 36:1722-8. 10.1016/j.cjca.2020.05.026
23. Ben-Chetrit E, Levy M: Colchicine prophylaxis in familial Mediterranean fever: reappraisal after 15 years. Semin Arthritis Rheum. 1991, 20:241-6. 10.1016/0049-0172(91)90019-v
24. Zemer D, Livneh A, Danon YL, Pras M, Sohar E: Long-term colchicine treatment in children with familial Mediterranean fever. Arthritis Rheum. 1991, 34:973-7. 10.1002/art.1780340806
25. Verma S, Eikelboom JW, Nidorf SM, Al-Omran M, Gupta N, Teoh H, Friedrich JO: Colchicine in cardiac disease: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2015, 15:96. 10.1186/s12872-015-0068-3
26. Siaik J, Flint N, Shmueli HG, Siegel RJ, Rader F: The use of colchicine in cardiovascular diseases: a systematic review. Am J Med. 2021, 134:735-744.e1. 10.1016/j.amjmed.2021.01.019